Astra cannot breathe easy despite first triplet approval
Astrazeneca hopes that its new COPD triplet can gain share from Glaxosmithkline’s rival, but it is not planning a price war.
Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Takeda casts doubt on the remaining approach to amyloidosis
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
Upcoming events – Anaptysbio and Retrophin await big readouts
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Time to restock big pharma’s leaking pipeline
The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.
Colorectal cancer could see Array stand alone at last
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
Upcoming events – Phase III data for Chiasma and Novartis
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Upcoming events – binary outcomes for Inflarx and Achieve
Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
Circassia averts its cash crunch
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.